Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

1.

Site-specific blockade of RAGE-Vd prevents amyloid-beta oligomer neurotoxicity.

Sturchler E, Galichet A, Weibel M, Leclerc E, Heizmann CW.

J Neurosci. 2008 May 14;28(20):5149-58. doi: 10.1523/JNEUROSCI.4878-07.2008.

2.

Mechanisms of beta-amyloid neurotoxicity: perspectives of pharmacotherapy.

Harkany T, Abrahám I, Kónya C, Nyakas C, Zarándi M, Penke B, Luiten PG.

Rev Neurosci. 2000;11(4):329-82. Review.

PMID:
11065280
3.

Preventing activation of receptor for advanced glycation endproducts in Alzheimer's disease.

Lue LF, Yan SD, Stern DM, Walker DG.

Curr Drug Targets CNS Neurol Disord. 2005 Jun;4(3):249-66. Review.

PMID:
15975028
4.

Structure-function implications in Alzheimer's disease: effect of Abeta oligomers at central synapses.

Cerpa W, Dinamarca MC, Inestrosa NC.

Curr Alzheimer Res. 2008 Jun;5(3):233-43. Review.

PMID:
18537540
5.

[Involvement of beta-amyloid in the etiology of Alzheimer's disease].

Tomiyama T.

Brain Nerve. 2010 Jul;62(7):691-9. Review. Japanese.

PMID:
20675873
6.

Crosstalk between calcium, amyloid beta and the receptor for advanced glycation endproducts in Alzheimer's disease.

Leclerc E, Sturchler E, Vetter SW, Heizmann CW.

Rev Neurosci. 2009;20(2):95-110. Review.

PMID:
19774788
7.

Amyloid-beta aggregation.

Finder VH, Glockshuber R.

Neurodegener Dis. 2007;4(1):13-27. Review.

PMID:
17429215
8.

Amyloid binding ligands as Alzheimer's disease therapies.

Lee VM.

Neurobiol Aging. 2002 Nov-Dec;23(6):1039-42. Review.

PMID:
12470800
9.
10.
11.

Regulated proteolysis of RAGE and AbetaPP as possible link between type 2 diabetes mellitus and Alzheimer's disease.

Kojro E, Postina R.

J Alzheimers Dis. 2009;16(4):865-78. doi: 10.3233/JAD-2009-0998. Review.

PMID:
19387119
12.

Binding sites of amyloid beta-peptide in cell plasma membrane and implications for Alzheimer's disease.

Verdier Y, Penke B.

Curr Protein Pept Sci. 2004 Feb;5(1):19-31. Review.

PMID:
14965318
13.

Cell degeneration induced by amyloid-beta peptides: implications for Alzheimer's disease.

Pereira C, Ferreiro E, Cardoso SM, de Oliveira CR.

J Mol Neurosci. 2004;23(1-2):97-104. Review.

PMID:
15126695
14.

Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease.

Deane R, Zlokovic BV.

Curr Alzheimer Res. 2007 Apr;4(2):191-7. Review.

PMID:
17430246
15.

A new insight on Al-maltolate-treated aged rabbit as Alzheimer's animal model.

Bharathi, Shamasundar NM, Sathyanarayana Rao TS, Dhanunjaya Naidu M, Ravid R, Rao KS.

Brain Res Rev. 2006 Sep;52(2):275-92. Review.

PMID:
16782202
16.

Always around, never the same: pathways of amyloid beta induced neurodegeneration throughout the pathogenic cascade of Alzheimer's disease.

Hoozemans JJ, Chafekar SM, Baas F, Eikelenboom P, Scheper W.

Curr Med Chem. 2006;13(22):2599-605. Review.

PMID:
17017913
17.

Intraneuronal Abeta accumulation and origin of plaques in Alzheimer's disease.

Gouras GK, Almeida CG, Takahashi RH.

Neurobiol Aging. 2005 Oct;26(9):1235-44. Review.

PMID:
16023263
18.

Signaling mechanisms underlying Abeta toxicity: potential therapeutic targets for Alzheimer's disease.

Smith WW, Gorospe M, Kusiak JW.

CNS Neurol Disord Drug Targets. 2006 Jun;5(3):355-61. Review.

PMID:
16787235
19.
20.

Alzheimer's disease-associated neurotoxic mechanisms and neuroprotective strategies.

Pereira C, Agostinho P, Moreira PI, Cardoso SM, Oliveira CR.

Curr Drug Targets CNS Neurol Disord. 2005 Aug;4(4):383-403. Review.

PMID:
16101556

Supplemental Content

Support Center